GenIP Plc (LSE:GNIP) reported strong operational momentum in 2025, delivering approximately 330% revenue growth and a 150% increase in gross margin compared with 2024, supported by rapid client acquisition and high retention levels.
Growth has been driven by increasing uptake of the group’s integrated invention intelligence platform, particularly its higher-margin Invention Prioritizer product. Recent contract wins include new orders from Brazil’s National Nuclear Energy Commission, while extensive deployment at a leading Saudi research university has generated referrals and inbound enquiries, highlighting growing international recognition of the platform’s capabilities.
GenIP is also making progress in the corporate sector, with demand for its Invention Evaluator product increasing through a partnership with 360 Impact Studio as well as through direct client engagements. Academic demand remains robust, with repeat and multi-year contracts secured from institutions across the US, Chile and Singapore, providing revenue visibility and reinforcing the company’s strong foothold in the research market.
To further strengthen market engagement, GenIP has launched a new webinar series, GenIP Innovation Exchange, designed to showcase how leading universities embed its tools within technology commercialisation workflows. Management views this initiative as a key step in broadening its corporate customer base and reinforcing its positioning as a provider of higher-value, AI-enabled innovation services.
More about GenIP Plc
GenIP Plc operates at the intersection of generative AI and innovation strategy, delivering AI-powered innovation intelligence and technology commercialisation services. Its core offering is the Invention Intelligence product suite, which provides insights into the commercial potential of emerging technologies. The group also offers talent and executive search services that apply machine learning and natural language processing to connect innovation-led organisations with commercialisation-focused leadership across corporate, venture capital and academic markets worldwide.
Leave a Reply